ArticlePsychopharmacology2014
Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype.
Article in Psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review.Frontiers in psychiatry · 2021Pooled it
- Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial.Psychopharmacology · 2019Trial
- Multilocus Genetic Profile Reflecting Low Dopaminergic Signaling Is Directly Associated with Obesity and Cardiometabolic Disorders Due to Antipsychotic Treatment.Pharmaceutics · 2023Article
- Metabolic Syndrome in Adults Receiving Clozapine; The Need for Pharmacist Support.Pharmacy (Basel, Switzerland) · 2023Article
- COMT Val158Met Polymorphism, Cardiometabolic Risk, and Nadir CD4 Synergistically Increase Risk of Neurocognitive Impairment in Men Living With HIV.Journal of acquired immune deficiency syndromes (1999) · 2019Article
- Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review.Neuropsychiatric disease and treatment · 2019Article
- Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics.Neuropsychiatric disease and treatment · 2019Article
- Precise treatments for schizophrenia: where is the way forward?General psychiatry · 2018Article
- Germline genetic variants with implications for disease risk and therapeutic outcomes.Physiological genomics · 2017Review
- Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis.The pharmacogenomics journal · 2017Article
- Clozapine Monitoring in Clinical Practice: Beyond the Mandatory Requirement.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2016Review
- COMT Val158Met polymorphism is associated with blood pressure and lipid levels in general families of Bama longevous area in China.International journal of clinical and experimental pathology · 2015Article
- Article
- Genetic variant in NDUFS1 gene is associated with schizophrenia and negative symptoms in Han Chinese.Journal of human genetics · 2015Article
- A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics.Psychopharmacology · 2014Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleMetabolic syndrome (MetS) has consistently been identified as an adverse effect of long-term treatment with atypical antipsychotics (AAPs) such as clozapine. Elevated serum homocysteine concentration has been found to act as an independent risk factor for MetS, and catechol-O-methyltransferase (COMT) catalyzes the homocysteine metabolism. We accordingly hypothesized that COMT dysregulation may confer the susceptibility to MetS induced by AAPs, potentially in a gender-specific manner, because the interaction effects of COMT and gender have been consistently reported.
objectivesThis study aimed at determining the prevalence and influence of COMT on MetS among a population undergoing long-term clozapine treatment.
methodsA total of 468 schizophrenia patients taking clozapine were divided into two groups, those experiencing MetS and non-MetS. We genotyped three functional variants (rs4633, rs4680, and rs4818) in COMT and measured the serum levels of fasting homocysteine, glucose, triglyceride (TG), and high-density lipoprotein cholesterol.
resultsMetS was found in 202/468 (43.2 %) of all the patients, with 40.2 % prevalence (138/343) in males and 51.2 % (64/125) in females. Patients with MetS had notably higher metabolic parameters than those without MetS. The mean levels of homocysteine in patients with MetS were significantly higher than those without MetS. We found a positive association between the rs4680 polymorphism and the serum triglyceride levels (corrected P = 0.024). Further analysis revealed that the rs4680 Met allele was significantly associated with increased triglyceride levels among female patients (P = 0.009), but not among males (P = 0.07).
conclusionsOur findings suggest a potential association between rs4680 in COMT and elevated TG levels, particularly among female patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.